Cold‐stored leukoreduced CPDA‐1 whole blood: in vitro quality and hemostatic properties
Autor: | Tor Hervig, Geir Strandenes, Hanne Braathen, Turid Helen Felli Lunde, Torunn Oveland Apelseth, Einar K. Kristoffersen, Joar Sivertsen |
---|---|
Rok vydání: | 2020 |
Předmět: |
Blood Platelets
Quality Control medicine.medical_specialty Platelet Aggregation Immunology In Vitro Techniques 030204 cardiovascular system & hematology Fibrinogen Hemolysis Phosphates 03 medical and health sciences 0302 clinical medicine Refrigeration Internal medicine White blood cell medicine Humans Immunology and Allergy Platelet Citrates Platelet activation Whole blood Blood Specimen Collection Hemostasis Hematology medicine.diagnostic_test Platelet Count business.industry Adenine Thromboelastography Cold Temperature Blood Glucose Leukoreduction medicine.anatomical_structure Blood Preservation Anesthesia Leukocyte Reduction Procedures business Filtration 030215 immunology medicine.drug |
Zdroj: | Transfusion. 60:1042-1049 |
ISSN: | 1537-2995 0041-1132 |
Popis: | Background Some jurisdictions require leukoreduction of cellular blood components. The only whole blood collection set with a platelet-saving filter uses citrate-phosphate-dextrose (CPD) as storage solution. Substituting CPD with citrate-phosphate-dextrose-adenine (CPDA-1) increases shelf life from 21 to 35 days. This would simplify prehospital and rural resupply and reduce wastage. We investigated in vitro quality and hemostatic properties of CPDA-1 whole blood leukoreduced with a platelet-saving filter. Study design and methods CPDA-1 whole blood was leukoreduced using a platelet-saving filter and stored 35 days. EDQM requirements, hematology, metabolic parameters, thromboelastography, light transmission aggregometry, fibrinogen, factor VIII, and interleukin-6 were measured on Days 0, 1, 14, 21, and 35 and compared to non-leukoreduced blood. Results All units met EDQM requirements. Leukoreduction yielded residual white blood cell count 0.8% was observed. Factor VIII was higher on Day 35 in the leukoreduced group, 37.9 (95% CI: 26.0, 49.8) versus 13.8 (9.4, 18.2) IU/dL. In both groups, aggregation was significantly reduced by Day 14. Thromboelastography showed remaining platelet activity on Day 35, MA 46.9 (42.1, 51.7) in the leukoreduced and 44.3 (39.6, 49.0) mm in the non-leukoreduced group. Fibrinogen was within reference ranges at Day 35 (>2 g/dL). Interleukin-6 was not detectable. Conclusion Leukoreducing CPDA-1 whole blood with a platelet-saving filter did not compromise hemostatic properties. We encourage development of a single bag CPDA-1 whole blood collection set with in-line platelet-saving filter. |
Databáze: | OpenAIRE |
Externí odkaz: |